Última actualización: Agosto 27, 2026
How Are Stem Cells Administered for Hearing Loss?
In cases of hearing loss associated with inner-ear dysfunction, previous infection, trauma, inflamación, or certain genetic disorders, mesenchymal stromal cell therapy is being investigated as a regenerative approach. The method of administration must always be selected individually after determining the precise cause and location of the hearing impairment.
The inner ear is a small, delicate, and anatomically difficult-to-access organ. Direct local injection into or near its structures is an invasive procedure that may damage residual hearing, the cochlea, the vestibular apparatus, or adjacent neural structures. Por esta razón, systemic intravenous administration may be considered as a less invasive method of introducing cells into the circulation.
The organs and tissues of the human body are interconnected through the vascular system and microcirculation. Following intravenous administration, the cells enter the bloodstream and interact with biological signals produced by injured, inflamed, or stressed tissues. These signals may include chemokines, citoquinas, moléculas de adhesión, y factores de crecimiento.
Mesenchymal stromal cells carry receptors capable of responding to some of these molecular signals. Este proceso se conoce como localización celular o quimiotaxis. Rather, molecular gradients may influence their adhesion, migración, and biological activity. research has identified signalling pathways such as SDF-1/CXCR4 as potentially relevant to cell migration toward injured cochlear tissues.
The possible therapeutic action is thought to depend mainly on paracrine signalling. Mesenchymal stromal cells release biologically active factors that may:
- modulate excessive inflammation;
- influence immune-cell activity;
- reduce cellular stress;
- support microvascular and endothelial function;
- stimulate survival and repair mechanisms in resident cells;
- promote a tissue environment more favourable to regeneration.
Depending on the underlying pathology, the affected structures may include cochlear hair cells, supporting cells, the stria vascularis, auditory neurons, the auditory nerve, or the inner-ear microcirculation. The potential cellular response may therefore differ considerably between hearing loss caused by inflammation or trauma and hearing loss resulting from an irreversible genetic defect.
Only very small numbers of endogenous progenitor cells normally circulate in peripheral blood, and their natural activity may be insufficient to reverse established chronic damage. In cell-therapy protocols, cells may therefore be isolated and expanded under controlled laboratory conditions to obtain a clinically defined dose. This process can take approximately seven days, depending on the source of the cells, the manufacturing protocol, and the required quality-control testing.
An intravenous dose—for example, 10 million or more cells
Revisión de casos científicos
¿Le gustaría saber si los programas clínicos actuales, desarrollos recientes de investigación, o enfoques emergentes pueden ser relevante para su situación individual?
Comparte tu pregunta con nuestro equipo de investigación científica y recibe información centrada en las áreas de investigación actuales que pueden ser relevante para su caso.
- Revisión de la información que proporcionas.
- Información relevante sobre programas clínicos y de investigación.
- Una respuesta clara y centrada en tu situación.
Sin compromiso. Su pregunta será revisada de forma confidencial..
Información educativa y de investigación únicamente.. Este servicio no constituye consejo médico, diagnóstico, prescripción, o un personalizado recomendación de tratamiento.
